Act makes it possible to seize and destroy even legitimately produced generic drugs exported from India to poor countries It was a triumphant moment for public health campaigners when members of the European Parliament voted against the Anti- Counterfeiting Trade Agreement (ACTA) on July 4. ACTA is a plurilateral pact, designed to protect against counterfeiting of products, including medicines. ACTA, primarily drafted and secretly negotiated by the US, was signed on October...

-The Hindu The World Health Organisation (WHO) has put in place a mechanism to define counterfeit medical products. The set of definitions of sub-standard, spurious, falsely labelled, falsified and counterfeit products will be globally accepted and help to bring about uniformity in identifying such drugs, without interrupting worldwide supplies. The decision to establish a member state mechanism was taken at the World Health Assembly, the WHO's policymaking body, at a meeting held recently. The...

-The Hindu Unnerved by the Indian stand, IT monopolies are propagating the myth that a multilateral governance structure will kill the decentralised, multi-stakeholder nature of the Internet and lead to ‘government control' Last year, in a statement to the U.N. General Assembly, India sought the creation of a U.N. Committee on Internet-Related Policies (CIRP) in order to democratise global Internet governance, which at present is either U.S.-controlled, or subject to the policies...

-PTI German pharma major Bayer has charged that Indian generic drugmaker Cipla had breached its patent rights by slashing the price of a generic version of its patent-protected cancer drug Nexavar last week. Bayer Pharma has not given its consent to Cipla to launch its generic Sorafenib (sold under the brand name Nexavar) and the company’s decision to cut the price of the life-extending kidney and liver cancer drug “is a clear...

India joins global drug discovery league The launch by Ranbaxy last week of Synriam, a new drug to treat malaria, is an important milestone. Having made its name by manufacturing generic (off patent) drugs cheaply, India’s pharmaceutical industry has struggled to achieve original drug discovery since the Uruguay Round of trade negotiations signalled the onset of product patents in India. It began to be realised, in time, that there was...